Study Information

Title: A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer External
Status: Recruiting participants
Conditions: Non-Small Cell Lung Cancer (ALK-positive); Non-Small Cell Lung Cancer (c-Met-amplified); Non-Small Cell Lung Cancer (ROS Marker Positive); Systemic Anaplastic Large-Cell Lymphoma
Interventions: Drug: PF-02341066; Drug: Rifampin; Drug: Itraconazole
Health Topics: Adenocarcinoma of the Lung, Lung Cancer Overview, Non-Hodgkin Lymphoma, Squamous cell carcinoma of the lung

Contact Information


Pfizer Investigational Site
Boston, MA 02114
Pfizer Investigational Site
Boston, MA 02115
Pfizer Investigational Site
Boston, MA 02215